Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA) and Prof Nicolas Mottet (University Hospital St Etienne, St Etienne, France) discuss the prostate cancer updates from ASCO and EAU 2022. Initially, they discuss the latest treatment options for prostate cancer.
They then talk about PARP combinations and monotherapies.
Prof Efstathiou mentions the results from the phase 3 HERO study that investigated sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer from EAU 2022.
They also talk about the further results from the phase III PROpel trial that investigated the tolerability of abiraterone combined with olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
The impact of PSMA PET/CT on prostate cancer salvage radiotherapy management is also discussed.
Prof Efstathiou and Prof Mottet also discuss the patient population and radiation therapy type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide added to androgen deprivation therapy in high-risk localised or locally advanced prostate cancer (HRLPC).